CTOs on the Move

Arresto BioSciences

www.arresto.com

 
Arresto BioSciences is a Palo Alto, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.arresto.com
  • 3183 Porter Dr
    Palo Alto, CA USA 94304
  • Phone: 650.352.5564

Executives

Name Title Contact Details

Similar Companies

Tarcine

Tarcine is a Thousand Oaks, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

The Public Health Company

PHC empowers organizations to proactively manage infectious disease risk through global disease forecasting, risk analysis, and practical guidance. PHC was founded by Dr. Charity Dean, and employs a world-class team of public health professionals, tech...

Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC™) targeting EphA2; BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA™ targeting Nectin-4 and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, MA.

BioExx Specialty Proteins

BioExx Specialty Proteins Ltd. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Horizon Discovery

Horizon builds human disease models and reagents derived from genetically-engineered cells that its customers use, or that are deployed on their behalf to: gain knowledge of the genetic drivers of disease; develop novel drugs or cell therapies targeted...